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An effective HIV vaccine will likely need to induce broad and potent CTL responses. Epitope-based vaccines offer significant potential for
inducing multi-specific CTL, but often require conjugation to T helper epitopes or carrier moieties to induce significant responses. We tested
hybrid DNA vaccines encoding one or more HIV or SIV CTL epitopes fused to a hepatitis B core antigen (HBcAg) carrier gene as a means to
improve the immunogenicity of epitope-based DNA vaccines. Immunization of mice with a HBcAg-HIV epitope DNA vaccine induced CD8+ T
cell responses that significantly exceeded levels induced with DNA encoding either the whole HIV antigen or the epitope alone. In rhesus
macaques, a multi-epitope hybrid HBcAg-SIV DNA vaccine induced CTL responses to 13 different epitopes, including 3 epitopes that were
previously not detected in SIV-infected macaques. These data demonstrate that immunization with hybrid HBcAg-epitope DNA vaccines is an
effective strategy to increase the magnitude and breadth of HIV-specific CTL responses.
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(McMichael and Rowland-Jones, 2001) and protective immu-
nity against different viral variants may require induction of
CTL responses against a broad range of epitopes, including
subdominant and conserved sequences.
DNA immunization effectively induces T cell responses,
including CTL (Donnelly et al., 1997), making this strategy an
attractive approach for vaccination against HIV. Studies in
nonhuman primates have shown that DNA vaccines afford
various levels of protection against challenge with avirulent or
pathogenic AIDS viruses (Amara et al., 2001; Barouch et al.,
2000; Boyer et al., 1997; Kent et al., 1998; Robinson et al.,
1999; Rosati et al., 2005; Singh et al., 2005). However, in most
studies, boosting with a viral vaccine vector, numerous booster
immunizations, or high doses of DNA was required to induce
strong CTL responses and suppress infection, suggesting that
new strategies are needed to improve DNA vaccine potency.
Fig. 1. Schematic of the chimeric hepatitis B core antigen-epitope plasmid
design. Vector elements include the human cytomegalovirus immediate early
promoter (CMVpro) with intron A sequences, the tissue plasminogen activation
signal peptide (TPAsigpep), the coding sequence for hepatitis B core antigen
(HBcAg), the bovine growth hormone polyadenylation signal (BGHpA), and
the pUC19 origin of replication. One to three CTL epitopes were inserted into
either the immunodominant loop or at the C-terminus of the HBcAg gene.
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CTL. Unlike whole antigens, epitope vaccines can be designed
to include the relevant epitopes while excluding sequences
outside epitope domains that can negatively influence immuno-
genicity (Collins et al., 1998; Gratton et al., 1998; Maggi et al.,
1994; Romagnani and Maggi, 1994). Epitope-based vaccines
can also induce more potent immune responses than whole
antigen vaccines (Ishioka et al., 1999; Restifo et al., 1995). The
combination of an epitope-based strategy in the context of a
DNA vaccine may, therefore, provide a highly effective
strategy to elicit HIV-specific CTL.
Epitopes often require conjugation to a longer, immuno-
genic T helper peptide (Restifo et al., 1995; Shirai et al., 1994;
Vitiello et al., 1995) or a carrier moiety (Griffiths et al., 1993;
Layton et al., 1993; Michel et al., 1988; Schlienger et al.,
1992; Schodel et al., 1994a) to achieve significant immuno-
genicity. The hepatitis B virus nucleocapsid antigen (HBcAg)
has been used as an efficient carrier moiety for peptide or
protein vaccines (Milich et al., 1995; Schodel et al., 1994a;
Ulrich et al., 1998), and immunization with purified hybrid
HBcAg-B cell epitope particles enhances antibody responses
against the carried epitope (Milich et al., 1995; Schodel et al.,
1994a; Tindle et al., 1994; Ulrich et al., 1998). This prompted
us to investigate HBcAg as a carrier for CTL epitopes in the
context of a DNA vaccine as a method to augment CTL
responses. Here, we demonstrate hybrid DNA vaccines
encoding HIV or SIV epitopes fused to a HBcAg carrier
gene increase CTL epitope immunogenicity in mice and can
be used to induce broad CTL responses against multiple
epitopes in nonhuman primates.
Results
Generation of HBcAg-epitope DNA vaccines
Heterologous epitopes can be inserted into either the
immunodominant antibody binding or the C-terminus regions
of the HBcAg gene without disrupting the core particle
(Borisova et al., 1996). To test this concept as a DNA vaccine,
an H-2Dd-restricted HIV CTL epitope, RGPGRAFVTI
(Takeshita et al., 1995) recognized in Balb/c mice, was in-
serted into the immunodominant region of a plasmid encoding
the HBcAg carrier gene (pHBc) (Fig. 1), resulting in the hybrid
DNA vaccine, pHBc-V3-10. To determine if the hybrid
vaccine expressed core particles, Vero cells were transfected
with pHBc-V3-10 and the supernatants were subjected to
sedimentation in a 20% glycerol cushion to pellet the core
particles. For comparison, supernatants from Vero cells
transfected with either the parent HBcAg vector (positive
control) or DNA encoding irrelevant antigen (negative control)
were also analyzed. Core particles were measured by ELISA
detection of a hepatitis B e antigen (HBeAg) epitope that is
exposed on particles expressed by the HBc plasmids due to
deletion of the C-terminal arginine-rich region of the HBcAg
gene. HBeAg was readily detected in the fraction from the
parent HBcAg carrier vector (pHBc) and the hybrid pHBc-V3-
10 vector, but not from DNA encoding the HIV envelope gene(pHIVgp120) (Fig. 2), confirming that the hybrid vector
expressed hepatitis B core particles.
A multi-epitope SIV DNA vaccine encoding19 SIVmac239-
specific CTL epitopes that bind the Mamu-A*01 MHC class I
molecule (Allen et al., 2001) was also generated. The epitopes
were inserted into either the internal region or C-terminus of the
HBcAg gene. Separation of epitopes onto different plasmids
reduces competition between epitopes (Rodriguez et al., 2002).
Therefore, the two immunodominant CTL epitopes, Gag181–189
CM9 and Tat28–35 SL8 (Allen et al., 2001), were inserted into 2
separate HBcAg vectors, and the remaining 16 epitopes were
separated among 7 additional vectors resulting in a cocktail of 9
hybrid HBc-SIV vectors, each carrying 1–3 epitopes (Table 1)
separated by two alanines. All 9 HBc-SIV vectors expressed
variable, but comparable, levels of core particles in vitro (data
not shown).
Hybrid HBcAg-epitope DNA vaccines increase epitope
immunogenicity
We investigated HBcAg for the ability to enhance the
immunogenicity of the HIV epitope. Groups of 8 Balb/c mice
were immunized with three 1 μg DNA doses of either the hybrid
vector (pHBc-V3-10) or a control vector encoding the same
epitope without carrier (pV3-10) using a gene gun to deliver the
DNA directly into the cells of the epidermis. A 3rd group of
mice was immunized with a co-delivery of the parent HBcAg
carrier and the epitope (pHBc+pV3-10) to determine if
expression of the HBcAg carrier gene on a separate plasmid is
sufficient to enhance epitope immunogenicity, and a 4th group
Fig. 2. Detection of hepatitis B core particles following plasmid expression in
vitro. Core particles in cell supernatants from transfected Vero cells were
pelleted through a glycerol cushion, resuspended in sample buffer, and detected
by a commercial ELISA kit that measures expression of a HBeAg epitope
revealed on truncated core particle. Pelleted supernatant from untransfected Vero
cells was used as a negative control. The plasmid pV3-10 expresses the HIV V3
epitope without carrier; pHBc expresses the HBcAg carrier; and pHBc-V3-10
expresses HBcAg containing the HIV V3 epitope inserted into the immuno-
dominant loop.
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antigen (pHIVgp120) so that the epitope-based approaches
could be compared to a whole gene approach. The pHIVgp120
plasmid encodes the same epitope in the context of its natural
sequences and was previously shown to induce significant
responses against this epitope in mice (Fuller and Haynes,Table 1
Mamu-A*01-restricted, SIV-specific CTL epitopes inserted into chimeric
HBcAg-SIV DNA vaccines
Vaccine vector CTL epitopes Sequence Insert position
1. pHBc-SIV-CM9 Gag181–189CM9 CTPYDINQM Internal
2. pHBc-SIV-SL8 Tat28–35SL8
a STPESANL Internal
3. pHBc-SIV-SI9 Env763–771SI9 SWPWQIEYI C-terminus
4. pHBc-SIV-A Vif144–152QA9 QVPSLQYLA C-terminus
Pol143–152LV10 LGPHYTPKIV
Env729–738ST10 SPPSYFQTHT
5. pHBc-SIV-B Env235–243CL9 CAPPGYALL C-terminus
Pol147–155YI9 YTPKIVGGI
Pol51–61EA11 EAPQFPHGSSA
6. pHBc-SIV-C Gag340–349VT10 VNPTLEEMLT Internal
Pol621–629SV9 STPPLVRLV




8. pHBc-SIV-E Pol474–483IL10 IYPGIKTKHL C-terminus
Env622–630TL9 TVPWPNASL
Pol957–964MI8 MTPAERLI
9. pHBc-SIV-F Pol588–596QV9 QVPKFHLPV C-terminus
Gag372–380LA9 LAPVPIPFA
Pol359–368GM10 GSPAIFQYTM
CTL epitopes were inserted into either an internal position replacing an
immunodominant antibody-binding region or the C-terminus of the HBcAg
gene. Multiple CTL epitopes in a single vaccine were separated by two alanines
and inserted in the order indicated.
a Since recognition of Tat_SL8 and Tat_TL8 by PBMC from infected
macaques is indistinguishable, they are considered the same epitope.1994). After the 2nd and 3rd DNA doses, HIV epitope-specific
IFN-γ and CTL responses were measured by ELISPOT (Fig.
3A) and 51Cr-release (Fig. 3B) assays, respectively. Results
from both assays were consistent and show that the hybrid HBc-
V3-10 DNA vaccine induced significantly higher CD8+ T cell
responses than either the epitope alone (pV3-10, P=0.0015) or
the whole HIVgp120 gene (pHIVenv, P<0.0001). The low
immune responses induced by the pHIVgp120 plasmid after 3
doses may be due to poor expression of the glycosylated native
protein in mouse cells (Grundner et al., 2004) and is consistent
with our previous findings where 4–5 doses were required to
induce a significant response (Fuller and Haynes, 1994). CD8+
T cell responses in mice immunized with pHBc-V3-10
increased after the 2nd boost despite the presence of high
antibody titers against the carrier HBcAg (>1:100,000) after
the 1st boost (not shown), indicating that pre-existing responses
against HBcAg did not prevent boosting of the HIV-specific
response. Co-delivery of the HBcAg plasmid with the CTLFig. 3. (A) Frequencies of HIV epitope-specific CD8+ T cell responses as
measured by IFN-γ ELISPOT 2 weeks after the first or second booster
immunization. (B) HIV epitope-specific cytotoxic T lymphocyte responses
measured 2 weeks after the second boost. DNA vaccine vectors: p7134=empty
vector backbone, pHBc=parent vector encoding hepatitis B core antigen,
pHIVgp120=whole HIVgp120, pV3-10=HIV CTL epitope, HBc-V3-10=HIV
CTL epitope inserted into HBcAg, HBcAg+V3-10=co-delivery of pHBc and
pV3-10.
Table 2
Tetramer-positive CD3+/CD8+ T cells induced in mice following immunization
with HIV epitope DNA vaccines
DNA vaccine Antigens %Tetramer-positive
CD3/CD8+ T lymphocytes
p7134 None, control empty plasmid 0.50
pHBc HBcAg 0.42
pV3-10 HIV CTL epitope 3.84
pHBc-V3-10 HIV CTL epitope fused to
HBcAg
5.84
pV3-15 HIV CTL and Th epitopes 6.59
pHBc-V3-15 HIV CTL and Th epitopes
fused to HBcAg
10.7
Pools of splenocytes from 4 mice per group were analyzed following a prime
and two booster immunizations.
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responses, demonstrating the necessity of linking the epitope to
the HBcAg gene. Immune responses were reduced in the group
receiving the co-delivery of separate pHBcAg and pV3-10
plasmids when compared to mice immunized with the pV3-10
alone (Fig. 3), an outcome that is likely due to competition for
transcription factors between the co-delivered plasmids. For
gene gun delivery formulation of two or more plasmids onto the
same gold beads results in the plasmids being delivered into the
same cell (Arrington et al., 2002) and competition between the
vectors for transcription factors within the same cell reduces
plasmid expression and immune responses (Arrington et al.,
2002; Hooper et al., 2003).
The amount of antigen expressed can influence the potency of
a DNA vaccine. To determine if differences in antigen
expression influenced the magnitude of the HIV-specific CD8+
T cell response induced by each DNA vaccine, mRNA
expression was analyzed by Northern blot. B16 cells were
transfected with pHBc, pHIVgp120, pHBc-V3-10, or pV3-10;
and Northern hybridization analysis was performed on total
RNA extracted from cell lysates using a synthetic probe specific
for the 5′ untranslated region in each plasmid. As shown in Fig.
4, mRNA from the pHIVgp120 (lane C) plasmid was
undetectable by Northern blot, although HIVgp120 could be
detected in cell supernatants by sandwich ELISA (not shown).
This result indicates that the higher immunogenicity observed
with the epitope-based vaccines when compared to the wholeFig. 4. mRNA expression by DNA vaccine plasmids. Total RNAwas extracted
from cell lysates of transfected B16 cells and analyzed by Northern blot
hybridization using a cDNA probe specific for the 5′ untranslated region of each
plasmid. Lane A: pHBc; lane B: negative control (cell lysate from untransfected
cells); lane C: pHIVgp120; lane D: pHBc-V3-10; lane E: pV3-10.gene vaccine was due, in part, to higher levels of antigen
expression. The hybrid vector, pHBc-V3-10 (lane D), expressed
lower levels of mRNA than its parent HBcAg carrier vector (lane
A). However, comparable levels of mRNA expression were seen
in pHBc-V3-10 (lane D) and its control vector, pV3-10 (plasmid
expressing the CTL epitope without HBcAg, lane E) indicating
that pHBc-V3-10 was able to induce higher CD8+ T cell
responses than pV3-10 by conferring enhanced immunogeni-
city, not expression, to the inserted epitope.
Linkage of CTL and T helper epitopes significantly
improves the ability of epitope-based vaccines to induce
CD8+ T cell responses (Ishioka et al., 1999; Shirai et al.,
1994; Vitiello et al., 1995). We therefore tested the effects of
inserting a linked HIV-specific CTL-T helper epitope into the
immunodominant region of HBcAg. A second hybrid DNA
vaccine, pHBc-V3-15, was generated that expresses a 15-mer
HIV-specific CTL-T helper epitope (V3-15) fused to the HBcAg
carrier gene. V3-15 is recognized by CD4+ T cells with the class
II molecule I-Ad and includes 10 overlapping amino acids
corresponding to the minimal H-2Dd-restricted V3-10 CTL
epitope (Takeshita et al., 1995). The immunogenicity of pHBc-
V3-15 was compared to a control DNA vaccine encoding the
linked CTL-T helper epitope in the absence of the HBcAg
carrier (pV3-15). For comparison, additional groups of mice
were immunized with the pHBc-V3-10 or pV3-10 vectors
encoding only the minimal CTL epitope, or negative control
vectors encoding either hepatitis core antigen (pHBc) or the
empty expression vector cassette, p7134. Following the 3rd
dose, CD8+ T cell responses were measured using H-2Dd MHC
class I tetramers complexed to the HIV V3-10 CTL epitope.
Consistent with our previous results, HBcAg enhanced the
immunogenicity of the inserted epitopes, resulting in a marked
elevation of the CD8+ T cell response (Table 2). Frequencies of
tetramer-positive cells increased from 3.84% (V3-10) to 5.84%
(pHBc-V3-10) when the epitope was expressed in the context of
HBcAg. Similarly, insertion of the longer CTL-T helper epitope
(V3-15) into HBcAg increased the frequency of tetramer-
positive cells from 6.59% (pV3-15) to 10.7% (pHBc-V3-15)
(Table 2). Interestingly, linking the CTL epitope fused to the
HIV-specific T helper epitope (pV3-15) or the HBc carrier
(HBc-V3-10) resulted in comparable frequencies of HIV-
specific CD8+ T cells (6.59% vs. 5.84%, respectively)
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similarly effective in enhancing CD8+ T cell responses.
However, pHBc-V3-15 DNA vaccine induced the highest
CD8+ T cell response demonstrating that combining the HBcAg
carrier and T helper epitope afforded a synergistic effect on the
resulting CD8+ T cell response.
Hybrid HBcAg-SIV epitope DNA vaccine induces CTL in
rhesus macaques
Vaccine strategies that work well in mice can fail in larger
species, including humans and nonhuman primates. Therefore,
we tested a hybrid HBcAg-SIV epitope DNA vaccine in rhesus
macaques. Six macaques were immunized with a hybrid HBc-
SIV DNA vaccine encoding a SIV gag-specific Mamu A*01-
restricted CTL epitope (Gag181–189CM9: CTPYDINQM)
(Allen et al., 1998) inserted into the immunodominant core
region. PBMC were isolated after the 3rd dose and assayed for
the presence of CM9-specific CD8+ T cells by cytolytic assay
and tetramer staining. Significant levels of CTL and tetramer-
positive cells were detected in 5 of the 6 monkeys (Table 3).
Levels of CTL and tetramer-positive cells correlated with the
levels of HBcAg-specific antibody and T cell proliferative
responses in each monkey, providing further evidence for an
adjuvant role of HBcAg (Table 3).
HBcAg-SIV CTL epitope DNA vaccines induce multi-specific
SIV-specific CTL responses in monkeys
An effective HIV vaccine may need to induce CTL responses
against multiple epitopes. We therefore tested the hybrid
HBcAg-epitope DNA vaccine strategy for the ability to induce
multi-specific CTL responses in rhesus macaques. Five Mamu-
A*01-positive rhesus macaques were immunized with 3 doses
(32 μg/dose) of an HBcAg-multi-epitope SIV DNA vaccine
encoding19 Mamu-A*01-restricted epitopes (Table 1), along
with a DNA vaccine expressing whole SIV tat to provide SIV-
specific T cell help. Macaques received 3 DNA doses spaced
12 weeks apart. PBMC were isolated 8 days after the third
immunization and assayed by ELISPOT for peptide-specific
CD8+ T cell responses against 8 representative epitopes
encoded by the vaccine. As shown in Fig. 5A, IFN-γ CD8+ TTable 3
Immunogenicity of a hybrid HBcAg-Mamu-A*01 SIV Gag181–189 CM9 CTL


















M95045 6 0.2 100 1.6
M95058 19 6.7 25,600 16.1
M96031 34 23.7 102,400 33.7
M96118 35 21.6 51,200 nd
M96123 38 26.6 409,600 nd
M94004 14 17.5 102,400 nd
a PBMC were restimulated in vitro with peptide for 2 weeks. nd=Not done.cell responses against 3–6 of the 8 epitopes tested were detected
in each macaque. The breadth of the response differed between
each animal with only the immunodominant Gag_CM9 (Allen
et al., 1998) detected in all 5 macaques.
CD8+ T cells that have cytolytic effector function may be
critical for control of HIV/SIV replication (Calarota et al., 2006;
Goulder et al., 2000; Yang et al., 1997), but IFN-γ-producing
CD8+ T cell responses detected by the ELISPOT assay do not
always correlate with the cytolytic effector response (Calarota et
al., 2006). To determine if the HBcAg-multi-epitope DNA
vaccine induced CD8+ T cells with cytolytic activity, a second
group of macaques was immunized with 3 doses of HBc-multi-
epitope DNAvaccine without the plasmid expressing whole tat,
and cytolytic effector responses were assayed by 51Cr-release
assay. As shown in Fig. 5B, the vaccine induced significant
CTL responses (≥10% lysis) to 5–7 epitopes in each monkey,
and the repertoire of the CTL response was distinct in each
monkey with only a single epitope (Env235–243 CL9) recognized
by all 3 macaques.
Among all 8 macaques immunized with the HBc-multi-
epitope vaccine, SIV-specific CD8+ T cell responses were
detected by either ELISPOTor CTL assay against a total of 13 of
the 19 epitopes. Our inability to detect CTL responses against 6
of the epitopes is not due to defective vector expression because
all 9 vectors resulted in comparable levels of HBcAg expression
(not shown). Analysis of the responses induced by each vector
(Table 1 and Fig. 5) shows that CTL were detected against at
least 1 epitope encoded by each vector containing either a single
epitope or multiple epitopes inserted at the C-terminus of the
HBcAg gene (Table 1, vectors 1–5, 8, and 9) but not those
vectors containing multiple epitopes inserted into the internal
position of HBcAg (Table 1, vectors 6 and 7). This suggests that
epitope presentation may be compromised when more than one
epitope is expressed within the immunodominant region of the
HBcAg gene. CTL responses were detected against 3 epitopes
(Pol51–61EA11, Env622–630TL9, and Env763–771SI9) that were
previously not observed in SIV-infected macaques (Allen et al.,
2001) suggesting that the DNA vaccine was able to induce
responses against epitopes that may be subdominant in the
context of a natural infection.
Discussion
Presentation of epitopes in the context of immunogenic
particles is an effective strategy to increase epitope immuno-
genicity in protein-based vaccines (Delpeyroux et al., 1986;
Michel et al., 1988; Schlienger et al., 1992; Schodel et al.,
1994b). We investigated this effect in the context of a DNA
vaccine encoding HIV and SIV CTL epitopes fused to the gene
encoding hepatitis B core antigen. Our results demonstrate that
hybrid HBc-CTL epitope DNA vaccines express core particles
in vitro, are more immunogenic than DNA vaccines encoding
either whole antigen or the epitope in the absence of carrier, and
can be used to induce responses against multiple CTL epitopes
in nonhuman primates.
The results reported here are consistent with previous studies
using, instead, hepatitis B surface antigen (HBsAg) as a carrier
Fig. 5. SIV-specific T cell responses in 5 Mamu-A*01-positive rhesus macaques immunized with 3 doses of a cocktail of 9 HBcAg-epitope DNAvaccines encoding 19
Mamu-A*01 CTL epitopes (Table 1) with (panel A) or without (panel B) a plasmid expressing the SIV tat gene. (A) CD8+ T cell responses measured by ELISPOT in
Mamu-A*01-positive macaques following the 3rd dose. Immunizations were spaced 4–8 weeks apart. Responses were measured 8 days after the final dose. In all
cases, background levels were less than 10 spot forming cells (SFC)/106 PBMC. Responses significantly higher than background levels (twice the SFCs from untreated
PBMC plus 20 spots) were considered positive. (B) Cytolytic T cell responses in 3 Mamu-A*01-positive rhesus macaques following the 3rd dose. Immunizations were
spaced 12 weeks apart. PBMCwere isolated 2 weeks after the 3rd dose and stimulated with peptide in a 14-day culture. CTL activity was measured at an effector:target
ratio of 20:1 in a 51Cr-release assay using peptide-pulsed B-LCLs from a Mamu-A*01+ rhesus macaque as targets. Data are expressed as net lysis after subtraction of
background lysis measured using irrelevant peptides (see Materials and methods) that bound the Mamu-A*01 molecule but were not encoded in the vaccine cocktail.
Background lysis in all cases was 1–3%.
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DNA vaccines (Fomsgaard et al., 1998; Le Borgne et al., 1998;
Major et al., 1995; Marsac et al., 2005; Puaux et al., 2004;
Wunderlich et al., 2000) and studies using HBcAg as a carrier in
DNA vaccines to enhance antibody responses against B cell
epitopes (Lesinski et al., 2001; Wu et al., 2005). Here, we
extend these findings to show that the HBcAg carrier gene can
be used to increase the immunogenicity of DNA vaccines
encoding CD8+ T cell epitopes.
The increased epitope immunogenicity was likely due, in
part, to the induction of potent T helper responses against the
HBcAg carrier (Milich et al., 1997b) but was dependent on the
linkage of the CTL epitope to HBcAg. Linking CTL epitopes to
T helper epitopes in peptide vaccines similarly increases CTL
responses (Restifo et al., 1995; Shirai et al., 1994; Vitiello et al.,
1995). Linked sequences may be more immunogenic because
epitopes longer than the 8- to10-mers that define most minimalCTL epitopes could be more effectively processed by antigen
presenting cells. In addition, linking the CTL epitope to HBcAg
or a T helper epitope may bring the CTL and Th cells closer
together allowing for more effective transmission of stimulatory
lymphokines secreted by T helper cells.
The HBc-epitope carrier likely increases epitope immuno-
genicity via its ability to self-assemble into a highly
immunogenic particle and present the epitope in the context
of the particle (Milich, 1988). Phagocytic macrophages can
process particulate antigens via the exogenous class I pathway
(Kovacsovics-Bankowski et al., 1993; Pfeifer et al., 1993), and
particulate protein-based vaccines induce CD8+ T cell res-
ponses via this mechanism (Griffiths et al., 1993; Layton et al.,
1993; Schirmbeck et al., 1995). Similarly, in vivo expression of
the hybrid HBcAg-epitope DNA vaccines may afford dual
presentation of T cell epitopes in the context of both the
endogenous (via intracellular expression of the epitopes) and
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particles) class I pathways.
Another factor that likely contributes to the adjuvant effects
of HBcAg is its ability to directly activate B cells to serve as
primary antigen presenting cells in vivo (Kratz et al., 1999;
Milich et al., 1997a). The high density of repetitive structural
features of HBcAg allows it to cross-link mIg receptors on naïve
B cells, leading to mIg-receptor-mediated uptake of HBcAg and
induction of the costimulatory molecules B7.1 and B7.2 (Milich
et al., 1997a). As a result, HBcAg can enhance naïve B cell APC
function as much as 105-fold as compared with non-B-cell APC
(Kratz et al., 1999). This feature is unique to HBcAg and likely
contributes to HBcAg being more immunogenic than HBsAg
(Hoofnagle et al., 1974). In this respect, HBcAg may be a more
effective carrier of foreign epitopes than HBsAg.
We previously showed gene gun DNA immunization
induced CD8+ T cell responses in rhesus macaques and
protected against challenge with a heterologous primary isolate
of SIV (Fuller et al., 2002). In that study, 7 DNA doses were
required before significant CTL responses were detected in all
animals. In contrast, the HBc-SIV epitope DNA vaccines used
here induced SIV-specific CD8+ CTL responses in all 14
immunized rhesus macaques after only 3 doses. In a separate
study, this HBc-epitope DNA vaccine was effectively used to
prime for CD8+ T cell responses in rhesus macaques that were
increased to unprecedented levels when boosted with a single
dose of recombinant modified vaccinia Ankara (MVA)
encoding the same CTL epitope (Allen et al., 2000b). In that
study, tetramer-positive CD8+ T cell frequencies of 1.2–20.0%
detected following a single MVA boost significantly exceeded
levels of 0.4–3.0% reported in a previous study where
macaques were boosted with the same MVA vaccine following
priming with a DNA vaccine encoding the same epitope but in
the absence of HBcAg carrier (Hanke et al., 1999). These
results suggest that immunization with hybrid HBc-epitope
DNA vaccines should reduce the number of doses required for
priming the immune response and improve the ability of
combined DNA prime-viral vector boost strategies to induce
CD8+ T cell responses.
The hybrid HBc-epitope DNA vaccines encoding multiple
epitopes induced multi-specific CTL responses in rhesus
macaques. Among 8 animals, responses were detected against
a total of 13 of the 19 epitopes encoded by the vaccine.
Interestingly, CTL responses against 3 epitopes previously not
recognized in macaques chronically infected with SIV (Allen et
al., 2001) were also detected, suggesting that the HBcAg-multi-
epitope vaccine induced responses against subdominant
epitopes. These observations support the potential for using
this approach to increase the breadth of CTL responses against
HIV.
In each macaque, the multi-epitope DNA vaccine induced
responses to different repertoire of epitopes. Inherent variability
in immune responsiveness to vaccination in the outbred
macaque species is a factor that likely contributed to this result.
Similarly, although 14 of the 19 CTL epitopes used in this
vaccine have been recognized in SIVmac239-infected Mamu-
A*01 macaques, each infected animal responded to a differentsubset of these epitopes, even at the same time-point post-
infection (Allen et al., 2001). Thus, an effective HIV multi-
epitope vaccine may need to include a broad range of epitopes
to ensure that vaccinated individuals will respond to a minimum
repertoire of epitopes needed for protection.
An important goal in the development of vaccine strategies
against HIV is to identify vaccines that enhance both the
potency and the breadth of the virus-specific CD8+ T cell
response. Here, we report that a hybrid HBc-epitope DNA
vaccine strategy can be used to increase epitope immuno-
genicity and induce broad CTL responses. The HBc-multi-
epitope DNA vaccine described here was recently tested for
immunotherapy in combination with an antiretroviral drug in
SIV-infected macaques (Fuller et al., 2006) and shown to
increase the magnitude and breadth of the virus-specific
CD8+ T cell response, and this effect was associated with
reduced viral load and prevention of disease progression
(Fuller et al., 2006). These studies demonstrate that the hybrid
HBc-epitope DNA vaccine strategy may be a promising
approach for treating or preventing HIV infection as well as
other diseases where inducing CTL is a goal.
Materials and methods
HIV epitope DNA vaccines
Expression vector PJV7134 (PowderJect Vaccines Inc.,
Madison, WI) contains the cytomegalovirus (CMV) immediate
early promoter/intron A sequences that transcribe the coding
sequence for the signal peptide of the human tissue plasminogen
activator (hTPA), followed by the bovine growth hormone
polyadenylation signal, pUC19 origin of replication, and
ampicillin resistance gene. A unique Bsp120I site at the end of
the hTPA coding region allows for translational fusions of CTL
epitopes to the signal peptide. To construct expression vectors
pV3-10 and pV3-15, complementary oligonucleotides respec-
tively encoding either the minimal H-2Dd-restricted HIV CTL
epitope, RGPGRAFVTI (HIV IIIB Env311–320 RI10) (Takeshita
et al., 1995) or the epitope embedded in the longer HIV-specific
T helper epitope, RIQRGPGRAFVTIGK (HIV IIIB Env308–322
RK15) (Shirai et al., 1994), and appropriate overhangs for
insertion into the Bsp120I site were synthesized (Biosource,
Camarillo, CA) with appropriate Bsp120I overhangs. PJV7134
was digested with Bsp120I (New England Biolabs, Beverly,
MA) and the oligonucleotides were annealed and ligated into the
Bsp120I site to generate the epitope expression plasmids pV3-
10 (CTL epitope) pV3-15 (CTL and Th epitopes).
Hybrid HBcAg-epitope DNA vaccines
The HBcAg carrier expression vector pHBc expresses
HBcAg under the control of the CMV immediate early/intron
A promoter (PJV7198, PowderJect Vaccines, Inc., Madison,
WI). HBcAg was truncated at amino acid 144 at the C-terminus
and fused to the human TPA signal peptide sequence at the N-
terminus. A unique Bsp120I restriction was added within the
immunodominant c/e1 region between amino acids 80 and 81,
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insertion of epitopes at either site (Lesinski et al., 2001). To
construct hybrid HBcAg-epitope DNA vaccines, pHBc was
digested with either Bsp120I or NotI. Oligonucleotides encod-
ing Bsp120I or NotI-flanked, codon-optimized HIVor SIV CTL
epitopes flanked with Bsp120I overhangs were synthesized,
annealed, and ligated into pHBc either at the immunodominant
region or the C-terminus of the HBcAg gene (Fig. 1). For inserts
containing multiple CTL epitopes (Table 1), each epitope was
separated and flanked by 2 alanines. Clones containing inserts
were identified by PCR as described (Lesinski et al., 2001) and
sequenced to confirm insertion of the correct coding sequences
and orientation.
HIVgp120 DNA vaccine
The expression plasmid pHIVgp120 encodes the glycopro-
tein 120 gene from HIVBru Env under the control of the CMV
immediate early promoter and was generated as described
(Fuller and Haynes, 1994).
SIV tat DNA vaccine
The SIV tat DNA vaccine encodes the entire SIV tat gene
from SIV17E-Fr under the control of the CMV immediate early
promoter and was generated as described (Vogel et al., 2003).
Detection of HBcAg particles
Vero cells were transfected with pHBc, pHBc-V3-10, or
pHIVgp120 using Polyfect Transfection Reagent (Qiagen,
Valencia, CA). Negative controls were untransfected cells.
Twenty-four hours after transfection, cell culture supernatants
were overlaid on a 20% glycerol cushion (20% glycerol in TE
buffer; 10 mM Tris, pH8 and 1 mM EDTA) and pelleted by
centrifugation for 3 h at 100,000×g. The partially purified
particles were resuspended in 200 μl TE buffer, and 75 μl was
analyzed for the presence of an HBeAg epitope exposed in
truncated HBcAg particles (Schodel et al., 1993) by Murex
HBeAg/anti-HBe kit (Dartford, UK) according to the manu-
facturer's instructions.
Rhesus macaques
Rhesus macaques were identified as Mamu-A*01-positive
by PCR-SSP and by direct sequencing as previously described
(Knapp et al., 1997). Macaques were maintained in accordance
with the NIH Guide to the Care and Use of Laboratory Animals
and under the approval of the University of Wisconsin Research
Animal Resource Center (RARC) review committee.
DNA immunizations
Plasmid DNAwas precipitated onto 1- to 3-μm gold particles
as previously described (Roy et al., 2000) at a rate of 2.0 μg
DNA/mg of gold. The plasmids pV3-10 and pHBc were co-
delivered into the same cells by coating 1.0 μg of each plasmidon the same gold beads. The 9 plasmids in the HBc-SIVepitope
cocktail vaccine were co-delivered by coating each plasmid on
separate gold particles that were mixed just prior to immuniza-
tion. Abdominal fur was clipped from 5- to 6-week-old Balb/c
mice (H-2Dd), and both abdominal and inner leg fur were
clipped from rhesus macaques just prior to DNA delivery.
DNA-coated gold particles were accelerated into the abdominal
skin of mice and into the skin of both the abdominal and
inguinal lymph node regions of rhesus macaques by particle
mediated epidermal delivery (PMED) using an XR-1 research
delivery device (PowderJect Vaccines, Inc., Madison, WI).
DNA/gold was delivered at a helium pressure of 400 lb/in.2
(psi) for mice and 500–600 psi for monkeys. Each delivery
consisted of either 0.5 mg (mice) or 1.0 mg (macaques) of gold
and 1.0 μg (mice) or 2.0 μg (monkeys) of DNA. A dose of 2 μg
(mice) or 32 μg (macaques) of DNA per immunization was
achieved by administering DNA into 2 or 16 sites in mice and
monkeys, respectively. Consecutive DNA immunizations were
spaced 4 (mice) or 8–12 (macaques) weeks apart.
IFN-γ ELISPOT assays
ELISPOT assays were performed on mouse splenocytes and
PBMC from rhesus macaques as previously described (Arring-
ton et al., 2002; Fuller et al., 2006).
Northern blot
Plasmid vectors pHBc-V3-10, pV3-10, or the parent pHBc
vector were transfected into B16 cells using Polyfect Transfec-
tion Reagent (Qiagen, Valencia, CA). B16 cells were used
because we have found they consistently express plasmid-
encoded genes well. After 40 h, cell lysates were collected and
total RNA extracted using the SV Total RNA Isolation kit
(Promega, Madison, WI). The Northern blot analysis was
standardized and performed as described (Gilman, 1997).
Specimens from different groups were assayed twice, in
parallel, and the results were consistent in terms of yield and
reproducibility. 10 μg of RNA was subjected to gel electro-
phoresis, transferred to nitrocellulose, and hybridized with a
[32P]dATP-labeled cDNA probe specific for the 5′ untranslated
region in each plasmid. A 0.24–9.5 kb RNA Ladder (Life
Technologies, Rockville, MD) was used to confirm correct sizes
of mRNA expressed by each plasmid.
HIV cytotoxicity assays
HIV cytotoxicity assays in mice were performed using
peptide-pulsed P815 cells labeled with 100 μCi of sodium
51chromate (NEN Life Sciences, Boston, MA) as previously
described (Fuller and Haynes, 1994).
Tetramer staining
Soluble tetramericMamu-A*01MHC class I/SIVGag181–189
CM9 (CTPYDINQM) or H-2Dd MHC class I/HIV Env311–320
RI10 (RGPGRAFVTI) peptide complexes were generated, and
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2000a). For macaques, 1×106 PBMC from 2-week CTL
cultures were washed in FACS buffer consisting of phosphate-
buffered saline (Gibco, Rockville, MD) with 2% fetal calf serum
(BioCell, Rancho Dominguez, CA). Cells were stained in the
dark in 100 μl FACS buffer with 0.1 μg Mamu-A*01-PE
tetramer, 10 μl anti-rhesus CD3 FITC-conjugated antibody
(BioSource, Camarillo, CA), and 1 μl anti-CD8+-PECy5
(Coulter, Fullerton, CA) for 30 min at room temperature. The
cells were then washed with FACS buffer and fixed with 450 μl
of 2% paraformaldehyde. Data were acquired on a Becton
Dickinson FACSCalibur instrument and analyzed using Cell-
Quest software (Becton Dickinson Immunocytometry Systems,
San Jose, CA). Background tetramer staining of PBMC was less
than 0.02% (data not shown).
For mice, frozen pooled splenocytes were thawed, washed,
and stained in the dark with 1 μg H-2Dd-PE tetramer in 70 μl
FACS buffer for 2 1/4 h followed by staining with 2 μl of anti-
mouse CD3-PerCP and 1 μl anti-mouse CD8-APC for an
additional 40min. Pooled splenocytes frommicewithin the same
group were used to obtain a sufficient number of cells for the
analysis. The cells were thenwashedwith FACS buffer and fixed
with 450 μl of 2% paraformaldehyde. Data were acquired on a
Becton Dickinson FACSCalibur instrument and analyzed using
FloJo software (Becton Dickinson Immunocytometry Systems,
San Jose, CA). Populations of tetramer-positive cells were
readily distinguished as a distinct subset frombackgroundCD3+/
CD8+ Tcells. Background tetramer staining of in vitro stimulated
cultures from naive mice was <0.08% (data not shown).
SIV cytotoxicity assays
The CTL activity of in vitro stimulated PBMC from rhesus
macaques was determined by a standard 51Cr-release using γ-
irradiated, peptide-pulsed B-LCLs from a Mamu-A*01+ rhesus
macaque as targets as previously described (Allen et al., 2000a).
Data reported for each CTL epitope are based on CTL assays
tested at 20:1 effector:target ratios and reflect %net-specific
lysis after background subtraction. Background lysis for each
macaque was 1–3% (data not shown) and was determined by
averaging the gross %lysis from each of 3 CTL assays using
irrelevant peptides (AAPTSAPV, LAPVPIPF, and STP-
PLVRLV) that bound the Mamu-A*01 molecule (Allen et al.,
2001), but was not included in the DNA vaccine. A response
was considered positive if the net-specific lysis was ≥10%.
HBcAg proliferation assay
Rhesus macaque PBMC were isolated by Ficoll density
gradient centrifugation and washed 3 times with RPMI 1640
supplemented with Human AB+ serum (R10AB). PBMC
(100,000/well) were aliquoted into 96-well round-bottomed
plates in quadruplicate in 150 μl R10AB. Purified HBcAg
protein was added at 1 μg/well in 50 μl R10AB. Medium
containing no antigen was added to negative control wells and
5 μg/ml ConAwas added to positive control wells. Plates were
incubated for 4 days before adding 1 μCi tritiated thymidine toeach well. After 16- to 18-h incubation in the presence of
radionucleotide, cells were harvested onto glass fiber mats and
counted via scintillation. Counts per minute (CPM) were
averaged for quadruplicate wells and stimulation indices were
calculated by dividing the average CPM obtained from test
wells by the average CPM from the negative control wells.
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